Bio News

Eli Lilly has sued mail-order pharmacies and others over alleged $200 million in rebate fraud involving the diabetes drug Trulicity. The defendants are accused of falsely claiming rebates as if they had dispensed the drug to patients, while actually reselling it to third-party wholesalers. Lilly is seeking a temporary restraining order to halt the alleged fraud and the return of the full rebate amount.

Biobook Team
biobookmedia@biobook.co.krAribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug
Biogen Signs $411 Million Deal With Trimtech for Neurodegenerative Diseases